Bionetix, Inc. (“Bionetix”) is a development stage biotech devoted to the development of innovative small molecule based new drugs. With the aim of providing novel solutions to patients with high unmet medical needs, Bionetix was founded in 2017 and has completed 3 rounds of successful fund-raising campaigns. As a result of the fund-raising, Bionetix has raised about 15M USD until present and developing 2 IND-ready stage candidates (NTX-101, topical glaucoma treatment and NTX-301 oral targeted anti-cancer agent) and other early stage programs.
The combination of unique operation system and industrial expertise of Bionetix team enables fast development of the 2 preclinical programs and efficient identification and incubation of novel innovative early stage programs. In 2019, 2 IND applications for bothe NTX-101 and 301 will be submitted and 2 phase I clinical trials are expected in early 2020.